MANGOCEUTICALS, INC.
No SEC Form 4 filings for $MGRX in the last 30 days.
See all $MGRX insider activity →Mangoceuticals (MGRX) and Nuclea Energy mutually ended their business combination agreement on Aug 19, 2026, due to failing to secure $15 million in PIPE financing by the Aug 21 deadline. The termination is mutual, with no fees or breaches alleged.
MANGOCEUTICALS, INC. (MGRX) filed an SEC Form 8-K — Termination of a Material Definitive Agreement. false 0001938046 0001938046 2026-08-19 2026-08-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
Mangoceuticals (MGRX) shares rose 31.9% pre-open to $0.5612 after its merger partner, Nuclea Energy, said it reached a regulatory and siting milestone via a memorandum of understanding to locate the Morpheus microreactor at Utah’s San Rafael Energy Lab. The MOU supports a planned business combination that remains subject to approvals, with earnings expected around Aug. 13.
Over the past 7 days, alphai's AI scored 2 news stories mentioning MGRX (MANGOCEUTICALS, INC.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 2 bearish.
Recent MGRX coverage spans mergers & acquisitions and corporate actions.
Deal termination removes a potential upside catalyst and may pressure the stock lower.
Termination removes merger upside and may pressure the stock.
The stock’s move is tied to incremental deal credibility and a tangible nuclear microreactor proof-of-concept, ahead of an Aug. 13 earnings window.
The stock jump is driven by merger-related headlines plus a Nasdaq compliance extension, but the deal still requires approvals.
The announced definitive deal is a direct catalyst for MGRX, with near-term trading driven by deal mechanics, exchange ratio, and regulatory/commercial roadmap expectations.
alphai scores every news story that mentions MGRX with an AI model for sentiment and relevance, and aggregates insider trades from MANGOCEUTICALS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Mangoceuticals (MGRX) and Nuclea Energy mutually ended their business combination agreement on Aug 19, 2026, due to failing to secure $15 million in PIPE financing by the Aug 21 deadline. The termination is mutual, with no fees or breaches alleged.
1 min readMANGOCEUTICALS, INC. (MGRX) filed an SEC Form 8-K — Termination of a Material Definitive Agreement. false 0001938046 0001938046 2026-08-19 2026-08-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
1 min readMangoceuticals (MGRX) shares rose 31.9% pre-open to $0.5612 after its merger partner, Nuclea Energy, said it reached a regulatory and siting milestone via a memorandum of understanding to locate the Morpheus microreactor at Utah’s San Rafael Energy Lab. The MOU supports a planned business combination that remains subject to approvals, with earnings expected around Aug. 13.
3 min readMangoceuticals (MGRX) shares rose more than 49% after hours after the company said it signed an MOU with Nuclea Energy to explore siting a nuclear test reactor at Utah’s San Rafael Energy Lab to support Nuclea’s Morpheus microreactor. Mangoceuticals and Nuclea have a July 30 business combination agreement, pending approvals. MGRX received a 180-day Nasdaq bid-price extension to Feb. 1, 2027.
4 min readMangoceuticals (MGRX) signed a definitive deal to combine with Nuclea Energy to advance Nuclea’s Morpheus nuclear microreactor to public markets. Nuclea shareholders will receive exchangeable shares in a new Mangoceuticals subsidiary, exchangeable one-for-one into MGRX common stock, subject to Nasdaq limits. MGRX closed at $0.29, down 46.88%, after a $0.16 to $2.75 52-week range.
4 min readMangoceuticals, Inc. (NASDAQ:MGRX) shares are trending on Thursday night. Shares of the public health and wellness company jumped 137.77% to $0.70 in after-hours trading on Thursday following the announcement of a definitive business combination with Nuclea Energy Inc., a developer of the Morpheus lead-cooled microreactor.
4 min readMangoceuticals (NASDAQ: MGRX) said it signed a definitive business combination agreement with Nuclea Energy to take Nuclea’s Morpheus lead-cooled microreactor public. A new Mangoceuticals subsidiary will amalgamate with Nuclea, with Nuclea shareholders receiving exchangeable shares. Closing is subject to Mangoceuticals and Nasdaq approvals, with rights capped at 19.99% until then.
4 min readNuclea Energy Inc. said it signed a definitive business combination agreement with Mangoceuticals, Inc. (NASDAQ: MGRX) to pursue a Nasdaq public listing for Nuclea. Nuclea shareholders will receive exchangeable shares tied to Mangoceuticals common stock, with former Nuclea holders owning about 96% and Mangoceuticals holders about 4% post-closing, subject to approvals and a 19.99% Nasdaq cap.
4 min readMANGOCEUTICALS, INC. (MGRX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-2.1 2 ex2-1.htm EX-2.1 Exhibit 2.1 Execution Version BUSINESS COMBINATION AGREEMENT THIS BUSINESS COMBINATION AGREEMENT (this “ Agreement ”) is made as of July 29, 2026 (the “ Execution Date ”), AMONG: MANGOCEUTICALS, INC. , a corporation incorporated under the Laws of the Sta
6 min readMANGOCEUTICALS, INC. (MGRX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 SUBSCRIPTION AGREEMENT IN MANGOCEUTICALS, INC. A. Subscription . This Agreement has been executed by __________________________, a/an ( Individual/Corporation/LLC/Trust/Partnership ) , residing and/or having a principal place of business
4 min read
